Dupilumab for recalcitrant Kimura disease

Dermatol Ther. 2022 Sep;35(9):e15674. doi: 10.1111/dth.15674. Epub 2022 Jul 11.

Authors

Francesco Bellinato¹, Maria Gaia Mastrosimini², Giulia Querzoli², Paolo Gisondi¹, Giampiero Girolomoni¹

Affiliations

¹ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
² Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

PMID: 35770515
DOI: 10.1111/dth.15674

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Kimura Disease*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab